# History and Physical

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Jack London (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET010-SYN-TD
- Date: 1915-08-04
- Fictional facility: St. Posthumous Health Center
- Fictional author: Eleanor Whitcombe-Ibe, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Reason for visit

Establishing care for tiredness and ankle swelling, with high blood pressure and abnormal kidney tests, and heavy drinking found at the visit: kidney, liver and alcohol tests, AUDIT and DSM-5-TR assessment, withdrawal planning, mood and safety, his writing schedule, and a nephrology consultation. **S**

## Historical basis

- He was born on January 12, 1876, in San Francisco, and his birth certificate named him John Griffith Chaney. His mother, Flora Wellman, had lived with William Chaney, an astrologer, who left before the birth; she married John London, who adopted and raised the boy. **D**
- He grew up poor and worked from boyhood: an oyster pirate at 15, on the fish patrol at 16, an able-bodied seaman at 17, and a tramp crossing America at 18, when he spent a month in jail. **D**
- He went to the Klondike gold fields in 1897, at 21, and came home with very little after suffering scurvy. **D**
- He became internationally famous with The Call of the Wild (1903) and The Sea Wolf (1904), completed more than 50 books between 1900 and 1916, was at his peak the highest paid writer in the United States, and pushed to write 1,000 words a day wherever he was. **D**
- From 1905 he bought land at Glen Ellen in the Sonoma Valley and built up his Beauty Ranch; Wolf House, his nearly finished stone and redwood home, burned on August 22, 1913, a crushing financial loss. The loss left him depressed, but he forced himself back to work. **D**
- On the voyage of his yacht Snark through the South Pacific (1907 to 1909), in the Solomon Islands he had sores that a physician in Fiji called yaws and a missionary said were not; his hands swelled and peeled and his toenails thickened, a malady the Australian specialists could not name; he spent five weeks in hospital in Australia, gave up the voyage, and blamed tropical light. He also had a 'silvery skin' that doctors called by old names for leprosy, which cleared without treatment in California. **D**
- Physicians writing since have interpreted his illnesses differently: the 'silvery skin' has been read as psoriasis; one review proposed that mercury used to treat yaws damaged his kidneys and caused a dermatitis of the hands, feet and face; others suggested lupus, gout, and the effects of tobacco, alcohol and diet on his blood pressure and kidneys. None is established. **R**
- In John Barleycorn (1913) he wrote of his drinking from the first time he got drunk, at five years old. He held that he was no born alcoholic and had acquired the taste, and described how at the ranch, after writing his thousand words between nine and eleven each morning, he began to take a cocktail before midday dinner and then alone, 'not for the sake of the taste, but for the effect of the drink.' **D**
- In July 1913 he had his appendix removed, and serious kidney damage was found; his physician diagnosed a significant kidney problem at that time. **D**
- In 1914 he went to Vera Cruz as a war correspondent in the Mexican Revolution and was ill with dysentery and rheumatism. **D**
- He spent February 24 to July 22, 1915, in Hawaii and sailed there again on December 16, 1915; his health was described that year as declining. **D**
- He married Bess Maddern in 1900; their daughters Joan and Bess were born in 1901 and 1902, and the marriage ended in divorce in 1905. He married Charmian Kittredge in November 1905. **D**

4 later historical claims are omitted because they describe events after the index age. See the teaching note.

These claims are historical evidence, not findings from a real modern examination.

## History of present illness

This fictional modern episode addresses the presenting concerns below. **S**

- Tired by afternoon, with swollen ankles, and frightened by the word 'kidneys' again. **S**
- He knows the drinking is hurting him and wants to stop without losing his work. **S**
- He wants to keep writing a thousand words every morning. **S**

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Medications and allergies

- Naproxen 500 mg oral tablet twice daily, bought over the counter at full strength and taken most days for about two years for knee and back pain; stopped at intake **S**
- Losartan 50 mg oral tablet once daily **S**
- Chlordiazepoxide 25 mg oral capsule, fixed five-day taper for alcohol withdrawal (four capsules on day 1, three on day 2, two on day 3, one on days 4 and 5), dispensed for five days only, with a daily telephone check **S**
- Thiamine 100 mg oral tablet once daily **S**
- Acetaminophen 500 mg oral tablet, one or two tablets up to four times a day as needed for pain, no more than 2,000 mg in a day, in place of naproxen **S**
- No known allergy **S**

## Past medical history

True biography with historical dates; these events are not part of the synthetic care timeline.

- 1897 to 1898: Scurvy in the gold fields in his early twenties; recovered **D** (CLM-0003)
- 1907 to 1909: Skin sores, swollen and peeling hands and feet, and a silvery skin during a long Pacific voyage, with five weeks in hospital; the hands recovered and the skin cleared without treatment; the diagnoses were never settled **R** (CLM-0006, CLM-0007)
- July 1913: Appendectomy, at which kidney damage was found **D** (CLM-0009)
- 1914: Dysentery and joint pain (described as rheumatism) while working abroad **D** (CLM-0010)

## Procedures and immunizations

- No procedures before this visit. **S**


## Family history

- No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.

## Measurements

Sodium: 139 mmol/L; Potassium: 4.6 mmol/L; Bicarbonate (total CO2): 22 mmol/L; Urea nitrogen: 28 mg/dL (high); Creatinine: 1.98 mg/dL (high); Glucose: 94 mg/dL; eGFR (CKD-EPI 1910): 43 mL/min/1.73 m² (low); Urine albumin-to-creatinine ratio: 240 mg/g (high); Uric acid: 8.4 mg/dL (high); Calcium: 9.2 mg/dL; Phosphate: 3.8 mg/dL; Parathyroid hormone, intact: 74 pg/mL (high); Hemoglobin: 13.6 g/dL; MCV: 101 fL (high); Platelets: 182 10*3/uL; AST: 68 U/L (high); ALT: 41 U/L; GGT: 186 U/L (high); Albumin: 4.1 g/dL; Total bilirubin: 0.9 mg/dL; INR: 1; PEth (alcohol marker): 410 ng/mL (high); HbA1c: 5.4%; Total cholesterol: 214 mg/dL (high); HDL cholesterol: 58 mg/dL; LDL cholesterol (calculated): 128 mg/dL; Triglycerides: 140 mg/dL; AUDIT: 27; PHQ-9: 9; GAD-7: 7. All results are synthetic.

BP 158/98 mmHg; pulse 92 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 97% on room air; weight 84.2 kg; BMI 28.1 kg/m². All vital signs are synthetic.

## Examination

Mental status: Alert, warm and quick; speech fluent, at times emphatic; mood 'worn down'; affect full; slight tremor of the outstretched hands; no psychotic symptoms; no thoughts of suicide or of harming anyone; insight good and judgment fair; PHQ-9 9 with item 9 scored 0; GAD-7 7. Functional status: Independent; still writes every morning but tires by afternoon; rides less than he did; knee and low back pain after riding. Physical examination is intentionally limited. **S**

## Safety assessment

Current ideation: absent; intent: absent; plan: absent; access reviewed: yes. Disposition: Outpatient care with close follow-up. Risk factors reviewed without detail: severe alcohol use disorder, a new chronic illness, financial pressure, mild depressive and anxiety symptoms, and firearms on the ranch. He agreed that the rifle and shotgun will be kept locked in the ranch office safe with the ammunition stored apart, and that he will not handle them after drinking. Chlordiazepoxide is dispensed for five days only, with a daily telephone check. A written safety plan was made with him, and the 988 Suicide & Crisis Lifeline (call or text 988) and the clinic's number were written on a card he carries. Safety is reviewed at every visit. This is synthetic and does not convert historical behavior into a current finding. **S**

## Assessment

1. Tiredness, ankle swelling and high blood pressure (158/98 mmHg) with a raised creatinine (1.98 mg/dL, eGFR 43) and albumin in the urine (240 mg/g), found at intake; a creatinine of 1.7 mg/dL at an insurance examination about fourteen months ago, by his account; chronicity and cause under evaluation with a nephrology consultation; status draft. **S**
2. Alcohol use disorder, severe (seven DSM-5-TR criteria): a bottle of whisky or more most days for years, a morning drink to steady his hands, failed attempts to cut down, and drinking despite knowing it harms his health; AUDIT 27; PEth 410 ng/mL; status draft. **S**
3. Daily self-directed naproxen for knee and back pain for about two years, stopped at intake; acetaminophen in its place; status draft. **S**
4. Cigarette smoking, about ten a day; not ready to stop while he stops drinking; status draft. **S**

## Plan

- Kidneys and blood pressure: creatinine with eGFR (CKD-EPI 1910), urine albumin-to-creatinine ratio and urinalysis with microscopy, electrolytes and bicarbonate, uric acid, calcium, phosphate and PTH, blood count, HbA1c and a lipid panel once; the earlier insurance creatinine obtained; ultrasound of the kidneys and liver; standardized office blood pressure at every visit and home readings. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension and depression monographs (2026) **S**
- Nephrology consultation to confirm the stage and cause of the kidney disease and advise on blood pressure, an SGLT2 inhibitor, medicines for alcohol use disorder at his kidney function, and pain relief. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021) **S**
- Losartan 50 mg daily from intake, raised to the maximum tolerated dose, with potassium and creatinine two to four weeks after each start or change, accepting a rise in creatinine of up to 30 percent; less salt. Guideline: KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension and depression monographs (2026) **S**
- Alcohol: AUDIT, DSM-5-TR criteria and PEth with consent; liver tests and FIB-4; a withdrawal-risk score (PAWSS) and outpatient withdrawal with a five-day chlordiazepoxide taper, daily telephone checks and thiamine; addiction-focused counseling with the clinic's addiction medicine team each week and mutual-help meetings if he wishes; PEth and liver tests at follow-up. Guideline: The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020); AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis (2025) **S**
- Pain and medicine safety: no naproxen, ibuprofen or other oral anti-inflammatory medicines; acetaminophen up to 2,000 mg a day; no opioids or tramadol with kidney disease and in early recovery, and none at all if naltrexone is started; any new medicine checked for kidney dosing. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension and depression monographs (2026) **S**
- Safety: a structured safety assessment, firearms locked with ammunition apart, small supplies of withdrawal medicine, a written safety plan, the 988 Suicide & Crisis Lifeline, and safety review at every visit. Guideline: VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); Depression and Suicide Risk in Adults: Screening (2023) **S**
- Work and recovery: keep the morning writing hours from nine to eleven; replace the late-morning drink with a swim or a ride; no alcohol kept in the writing room; PHQ-9 and GAD-7 at intake and follow-up. Guideline: VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); Depression and Suicide Risk in Adults: Screening (2023) **S**
- Tobacco: advice to stop, with nicotine replacement or varenicline offered when he is ready. Guideline: Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021) **S**

## Guideline basis

- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney Int 2024;105(4S):S117-S314)
- KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021), Kidney Disease: Improving Global Outcomes (Kidney International)
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (Circulation 2025;152(11):e114-e218)
- CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension and depression monographs (2026), Aether Forge
- The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018), American Psychiatric Association (Am J Psychiatry 2018;175(1):86-90)
- VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021), United States Department of Veterans Affairs and Department of Defense
- The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020), American Society of Addiction Medicine (Journal of Addiction Medicine)
- AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis (2025), American Association for the Study of Liver Diseases (Hepatology)
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force
- Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021), U.S. Preventive Services Task Force
